Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > PFOF?

<< Previous

Bullboard Posts

Next >>

Post by stocksarefunon Dec 22, 2021 9:45am

136 Views

Post# 34253988

PFOF?

I regularly see posts like '10k shares available to $5' on CEO and sometimes here. If that were the case, why wouldn't someone with a 200k+ share position just buy 10k shares at market prices to lift the price?

Is there PFOF fudgery happening? whereby short shares will intantly be created to sell to the buyers instead of market level 2 orders being filled, Thus keeping the price stagnant?

Always curious of the mechanics of the canadian markets

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading